Gennev

“Gennev is proud to join Buoy in expanding access for women to receive specialized menopause care, enabling them thrive through their post-reproductive years,” said Jill Angelo, Gennev Founder and CEO.

SEATTLE (PRWEB)
October 31, 2022

The Feminina Group, DBA Gennev, is excited to announce that it has joined Buoy Health’s innovative healthcare marketplace to bring specialized menopause care to Buoy’s more than 2.5M users per month. Gennev joins a vibrant and expanding network of more than three dozen proven health delivery solutions committed to improving access to digital-first care—creating an all-in-one, holistic healthcare pathway from first symptoms to final treatment that delivers quality, cost-effective care for everyone.

“Gennev is proud to join Buoy in expanding access for women to receive specialized menopause care, enabling them thrive through their post-reproductive years,” said Jill Angelo, Gennev Founder and CEO.

Buoy has revolutionized the digital health landscape by equipping users with free AI-driven tools and reliable information from medical experts to better understand their health issues and match with the best care solution. Based on their self-reported symptoms, users are served up a personalized slate of care options and selections within Buoy’s healthcare marketplace. As a new member of the marketplace, Gennev will now be featured as an option for users when relevant to their healthcare journey.

“Our top priority as a healthcare matchmaker is to guide people to well-informed, relevant and timely care sources via our state-of-the-art algorithms and medical engine.” said Adrienne McFadden, Chief Medical Officer, Buoy Health. “Expanding our marketplace partners with innovative solutions like Gennev empowers us to build our promise to curate a diverse range of care options that make choice of relevant care and choice a reality, while keeping usability top of mind.”

“So many women suffer needlessly through menopause, even though relief from the 40+ symptoms can be as simple as a doctor visit away,” says Angelo. “Gennev’s mission is to improve the standard of care for women in menopause, and we do so with evidence-based therapies delivered by menopause-trained, board certified OB/GYNs, as well as health coaches who are also registered dietitian nutritionists. This approach provides not only the medical attention women need in their post-reproductive years, but also the lifestyle strategies that enable them to live their healthiest life, and thrive through menopause.”

About Gennev

Gennev provides telehealth practices with board certified, menopause-trained OB/GYNs, coaching with registered dietitians, health and wellness products, community conversations, and free education. Thousands of women have completed the Gennev Menopause Assessment to understand where they are in the journey and receive recommended health and wellness solutions. Gennev has been listening to thousands of women and the challenges they face with menopause today. For more information, visit https://gennev.com.

Share article on social media or email:

For clinical radiopharmaceutical studies, the broader team must understand the background of radiation dosimetry, radiation toxicity, normal organ dose constraints and how to capture these metrics within clinical trial data management.

TORONTO (PRWEB)
October 31, 2022

As the radiopharmaceutical research and development landscape continues to advance, so do the complexities and challenges associated with clinical trials. Conducting radiopharmaceutical trials presents a unique set of obstacles, such as the challenge of capturing unique radiation induced toxicities in the context of enrolled patients’ overall radiation exposure. This requires an understanding of enrolled patients’ cumulative radiation exposure from previous radiation treatments and current studies. For clinical radiopharmaceutical studies, the broader team must understand the background of radiation dosimetry, radiation toxicity, normal organ dose constraints and how to capture these metrics within clinical trial data management.

In this webinar, Medpace medical, operational, regulatory and core lab experts will explore considerations for radiation toxicity and analyze previous radiopharmaceutical case studies and draw on their 30+ years of integrated, global experience to examine strategies to successfully operationalize complex radiopharmaceutical trials and increase the probability of clinical and regulatory success.

Register for this webinar to learn how sponsors in the pharma and biotech industry can overcome challenges associated with complex radiopharmaceutical trials through medical, regulatory and operational considerations, including engaging an experienced and full-service clinical research partner with cross-functional expertise.

Click here to learn more about Medpace’s radiation therapy solutions.

Join experts from Medpace, Jess Guarnaschelli, MD, Senior Medical Director, Medical Department; Stephanie Millin, PhD, Clinical Trial Manager; Deborah Hirscher, MBA, MS, RN, ARNP, FNP, Senior Director, Clinical Trial Management; James Thomas, BSc (Hons), MA, Senior Director, Regulatory Submissions; and Daphnée Villoing, PhD, Dosimetry Specialist and Senior Project Manager, for the live webinar on Wednesday, November 16, 2022, at 9:30am EST (3:30pm CET/EU-Central).

For more information, or to register for this event, visit Radiation Toxicity — Considerations for Implementing Radiation Dose Limits in Radiopharmaceutical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

JUPITER, Fla. (PRWEB)
October 31, 2022

Advancements with Ted Danson is excited to announce the broadcast of an upcoming episode, scheduled to air on Saturday, November 5th at 8:00 pm ET in primetime on Bloomberg.

The growth of social media and online publications can make it difficult for people to know what information to trust, especially when science and medicine are involved. In this episode, Advancements will explore how improvements in research across the drug discovery and development trajectory are bringing trustworthy, relevant, and easily understandable information to the public. Viewers will discover how AAPS provides the right tools for identifying trustworthy science while also providing scientists with access to research outside their own disciplines.

With complex rules and complicated language – Americans often have a difficult time deciphering and understanding healthcare benefits and coverage. Advancements will go behind-the-scenes at Healthee to explore how innovations in artificial intelligence are empowering employees to better understand, access, and utilize benefits via real-time relevant and accurate information about coverage, care, and related costs.

With a look at some of the issues currently impacting the brain recovery journey –from the invisible nature of injuries to late and expensive therapeutic inventions– viewers will learn how Neurovine is merging concussion research with accessible technology to help give patients control over recovery. Audiences will learn how Neurovine’s AI-driven software system works to speed concussion recovery by supporting prognosis, delivering early targeted therapeutic interventions, and tracking patient and clinical progress.

Hearing from experts in the field, as well as several pharmacists, this segment will uncover the latest developments in pharmacy technology as it discovers how ImpactPharm is connecting patients with pharmacists via its patient platform that acts as an ecosystem to affordable care. Spectators will see how ImpactPharm is making pharmacist services accessible for patients, reducing the time of waiting in line, and ultimately bridging-the-gap in patient care.

“This episode is going to be well received by audiences and we look forward to exploring these amazing topics and technologies with viewers,” said Dustin Schwarz, director of programming, DMG Productions and the Advancements series.

###

About Advancements and DMG Productions:

Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics impacting society today, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative solutions responsible for shaping, molding, and transforming our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks.

For more information, please visit http://www.AdvancementsTV.com or call 866-496-4065.

Share article on social media or email: